Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C27H33N3O3S.C2HF3O2 |
||||||||||
Molecular Weight | 593.66 | CAS No. | 1217457-86-7 | ||||||||
Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (168.44 mM) | ||||||||
Ethanol | 100 mg/mL (168.44 mM) | ||||||||||
Water | Insoluble | ||||||||||
In vivo (Add solvents to the product individually and in order) |
|
||||||||||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | GGTI 298 is a geranylgeranyltransferase I inhibitor with ability to arrest human tumor cells in the G1 phase of the cell cycle and induce apoptosis. | |
---|---|---|
Targets |
|
|
In vitro | The geranylgeranyltransferase I inhibitor GGTI-298 has been shown to arrest human tumor cells in the G1 phase of the cell cycle and induce apoptosis. Treatment of the human lung carcinoma cell line Calu-1 with GGTI-298 results in inhibition of the phosphorylation of retinoblastoma protein, a critical step for G1/S transition. The kinase activities of two G1/S cyclin-dependent kinases, CDK2 and CDK4, are inhibited in Calu-1 cells treated with GGTI-298. GGTI-298 has little effect on the expression levels of CDK2, CDK4, CDK6, cyclins D1 and E, but decreases the levels of cyclin A. GGTI-298 increases the levels of the cyclin-dependent kinase inhibitors p21 and p15 and had little effect on those of p27 and p16. GGTI-298 promotes binding of p21 and p27 to CDK2 while decreasing their binding to CDK6. Its treatment results in an increased binding of p15 to CDK4, which is paralleled with decreased binding to p27. Pretreatment of fibroblasts with GGTI-298, blocks PDGF- and epidermal growth factor-dependent tyrosine phosphorylation of their corresponding tyrosine kinase receptors. GGTI-298 has antiproliferative effects on fibroblasts, epithelial, and smooth muscle cells, and this cell growth inhibition appears to be mediated through a G1 phase arrest[1]. |
|
In vivo | GGTI-298 inhibits tumor growth in nude mice[3]. |
Cell Assay: |
|
---|---|
Animal Study: |
|
|
Cholesterol biosynthesis inhibition synergizes with AKT inhibitors in triple-negative breast cancer [ bioRxiv, 2024, 10.1101/2024.01.16.575899] | PubMed: none |
Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment resistant melanomas [ Nat Commun, 2023, 14(1):3251] | PubMed: 37277330 |
Mevalonate Pathway-mediated ER Homeostasis Is Required for Haploid Stability in Human Somatic Cells [ Cell Struct Funct, 2021, 46(1):1-9] | PubMed: 33361684 |
Cellular basis underlying the intolerance to haploidy in vertebrates [ HOKKAIDO UNIVERSITY, 2021, 10.14943/doctoral.k14392] | PubMed: None |
Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase [ J Lipid Res, 2020, 61(12):1675-1686] | PubMed: 33109681 |
LUBAC controls chromosome alignment by targeting CENP-E to attached kinetochores [ Nat Commun, 2019, 10(1):273] | PubMed: 30655516 |
FBXW7 regulates endothelial barrier function by suppression of the cholesterol synthesis pathway and prenylation of RhoB [ Mol Biol Cell, 2019, 30(5):607-621] | PubMed: 30601691 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. [ Oncol Rep, 2018, 40(4):2171-2182] | PubMed: 30106444 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells [ Oncol Rep, 2018, 40(4):2171-2182] | PubMed: 30106444 |
Palmitoylated SCP1 is targeted to the plasma membrane and negatively regulates angiogenesis [ Elife, 2017, 6e22058] | PubMed: 28440748 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.